Friday, April 20, 2012

Novo Nordisk says it wont remove Victoza (liraglutide) in response to a public citize petition

As per a public citizen petition to the USFDA, Victoza should be immediately removed from the market as it is associated with higher risk of acute pancreatitis, thyroid cancer, serious allergic reactions and kidney failure, which outweighs any benefit that the drug may offer. In the first 17 months of Victoza on the market, 200 patients have been diagnosed with Acute pancreatitis (FDA adverse event database). The actual case of AP could be much higher due to under reporting.